Passage Bio, Inc. (PASG) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for holding. Good morning and welcome to the Passage Bio first quarter 2022 financial and operating results conference call. All participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised this call is being recorded at the company's request. At this time, I'd like to turn the call over to Stuart Henderson, Vice President of Corporate Development and Investor Relations. Stuart, please proceed. Thank you, Operator. This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available on the Passage Bio website under the Press Releases and Statements section of Investors & News. On today's call, Bruce Goldsmith, President and Chief Executive Officer, will review our first quarter 2022 and recent business highlights, and Simona King, our Chief Financial Officer, will review our first quarter 2022 financial results. Before we begin, please note that today's call may include a number of forward-looking statements, including but not limited to comments on our expectations about timing and execution of anticipated milestones, including the initiation of clinical trials and the availability of clinical data from such trials, our expectation about our collaborators' and partners' ability to execute key initiatives, the ability of our lead product candidates to treat their respective target CNS disorder, manufacturing plans and strategies, trends with respect to financial performance and cash flows, the company's ability to fund research and development programs, impact of the COVID-19 pandemic on the company's operations, and its ability to manage costs along with the uses of cash and other matters. These forward-looking statements are based on assump...